CLOS
BEAM icon

Compagnie Lombard Odier SCmA’s Beam Therapeutics BEAM Stock Holding History

Compagnie Lombard Odier SCmA’s Portfolio BEAM Stock Details BEAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-1,080
Closed -$42K – 639
2022
Q2 		$42K Hold
1,080
– – ﹤0.01% 463
2022
Q1 		$62K Buy
+1,080
New +$70.8K ﹤0.01% 422

Other funds holding BEAM

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
MM
MWG Management Road Town, Tortola, British Virgin Islands $81.3M AUM 2.28% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Compagnie Lombard Odier SCmA's BEAM Position: Q3 2022 in Review

Compagnie Lombard Odier SCmA sold out of Beam Therapeutics (BEAM) in Q3 2022, closing a stake of 1,080 shares — an estimated $42K sold.

Compagnie Lombard Odier SCmA first reported a position in BEAM in Q1 2022 and held it in 2 quarters. The position peaked at $62K in Q1 2022. 224 funds tracked by Wall St. Rank hold BEAM as of Q3 2022.

  • Compagnie Lombard Odier SCmA reported no remaining Beam Therapeutics position as of Q3 2022 after selling out during the quarter.
  • Compagnie Lombard Odier SCmA sold 1,080 Beam Therapeutics shares in Q3 2022, an estimated $42K.
  • Compagnie Lombard Odier SCmA first reported a position in Beam Therapeutics in Q1 2022 and held it in 2 quarters.
  • Compagnie Lombard Odier SCmA's Beam Therapeutics position peaked at $62K in Q1 2022.
  • 224 funds tracked by Wall St. Rank held Beam Therapeutics as of Q3 2022.

Based on Compagnie Lombard Odier SCmA's 13F filing for Q3 2022, filed 9 Nov 2022.